Navigation Links
Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
Date:2/5/2009

PRINCETON, N.J., Feb. 5 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, today announced the publication of data from a phase I/II study of nonpegylated liposomal doxorubicin (Myocet(R)) in the January 1 issue of Clinical Cancer Research. The study was supported by a grant from Roche and was conducted by the Spanish Breast Cancer Cooperative Group (SOLTI).

The study results suggest that Myocet(R), in combination with the approved trastuzumab (Herceptin(R)) plus paclitaxel (Taxol) treatment regimen, yielded an unusually high clinical response rate in patients with HER-2 overexpressing breast cancer. The 3-drug combination was well tolerated. There were no cases of treatment-related symptomatic congestive heart failure. This is noteworthy because cardiotoxicity is a common and therapy-limiting adverse event of the anthracycline class of anti-cancer agents and because Herceptin(R) has its own, well recognized, potential for cardiac toxicity.

Myocet is a liposomal delivery system for doxorubicin designed to reduce the risk of cardiotoxicity associated with doxorubicin while preserving its antitumor efficacy. It is currently in Phase III development in the United States for the treatment of advanced breast cancer.

"These clinical results are encouraging because they suggest that use of a nonpegylated liposomal anthracycline, such as Myocet, may provide important therapeutic benefits, while diminishing cardiac toxicity," said Ronald H. Goldfarb, Ph.D., President and CEO of Sopherion Therapeutics. "Moreover, the incidence of hand foot syndrome, a rate limiting toxicity of other liposomal anthracyclines, is rare with nonpegylated liposomal anthracyclines. We look forward to reporting additional data from ongoing Myocet clinical trials, which further test this concept in patients with advanced breast cancer."<
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
2. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
3. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
4. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
5. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
8. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
9. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
11. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Clinverse, Inc. , a ... trials, today announced it will be exhibiting and ... in Boston, June 24-26, 2013. Clinverse’s eClinical ... fully configurable, cloud-based clinical financial lifecycle system. , ... Clinverse’s eClinical Commerce Network, automates site contract set-up ...
(Date:6/19/2013)... June 19, 2013 Bayer CropScience will ... Bayer Bee Care Community Leadership Award. The award will ... Congressional Reception in Washington, D.C., an event where supporters ... the world’s food supply. , The Bayer Bee ... the power of the honey bee colony to benefit ...
(Date:6/19/2013)... Canada (PRWEB) June 19, 2013 ... trial business can potentially be worth up to ... this opportunity, the Indian government is taking serious ... trials the process. , This presentation will examine:, ... trial regulations ,     Immediate and long term ...
(Date:6/18/2013)... June 18, 2013 Tabletop SEMs are ... SEMs but have limited performance and capability such as ... size SEMs would normally provide better imaging performance and ... operate and have a higher cost of maintenance. ... gap between these two types of SEM product, offering ...
Breaking Biology Technology:Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 4Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 2Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 3
... 19, 2011 , , • ... MS drug with neuroprotective effects that does not cause,immunosuppression. ... the first,to be administered orally, whereas the few treatments ... significant side effects. • NeuroAdvan, the ...
... Mosquitoes die soon after a blood meal if certain ... at the University of Arizona has discovered. The ... the worldwide effort to curb mosquito-borne diseases like dengue ... blocked a cellular process known as vesicle transport, on ...
... dots made from cadmium and selenium degrade in soil, ... a University at Buffalo study has found. The ... Science and Technology , demonstrates the importance of learning ... -- interact with the environment after disposal, said Diana ...
Cached Biology Technology:Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 2Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 3Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 4Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 5Making blood-sucking deadly for mosquitoes 2Making blood-sucking deadly for mosquitoes 3Making blood-sucking deadly for mosquitoes 4Cadmium selenide quantum dots degrade in soil, releasing their toxic guts, study finds 2Cadmium selenide quantum dots degrade in soil, releasing their toxic guts, study finds 3
(Date:6/18/2013)... University of Calgary,s Faculty of Medicine have discovered a ... harmful bacteria. Platelets, a component of blood typically associated ... bacteria, and upon detection, seal it off from the ... in Nature Immunology this week, provide the ... "The science community has known that platelets do participate ...
(Date:6/18/2013)... Research Council, Laboratory of Molecular Biology, has been ... Young Investigator Award. Torrent is being recognized for ... algorithm to predict antimicrobial regions in proteins. Luis ... now applying this algorithm to interrogate full genomes ... with very appealing results." , Torrent obtained ...
(Date:6/18/2013)... It is estimated that between 5% and 10% of ... is to say that these tumours are attributable to ... BRCA1 or BRCA2. In patients with these mutations, PARP ... encouraging results that make them a new option for ... the latest studies indicate that a fraction of these ...
Breaking Biology News(10 mins):Immunity mechanism discovered 2The American Society for Microbiology honors Marc Torrent 2An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
... blocks the brain’s ability to strengthen connections at inhibitory synapses, ... The findings, uncovered in the laboratory of Brown scientist Julie ... brain. The research also supports a provocative new theory of ... "We’ve added a new piece to the puzzle of how ...
... three sexually active older adults infected with HIV has unprotected ... survey of 260 HIV-positive older adults found that of those ... a relationship. , AIDs cases among the over-50 crowd reached ... and Prevention, they will account for half of all HIV/AIDS ...
... Beucken and John Jansen have given body implants a DNA ... of the surrounding tissue and less immune responses. The older ... placing such parts yielded advantages, but also disadvantages such as ... easier and more reliable to use implants and has already ...
Cached Biology News:Morphine makes lasting -- and surprising -- change in the brain 21/3 of sexually active older adults with HIV/AIDs has unprotected sex 2DNA layer reduces risk of reserve parts being rejected 2
... sulfate-free, powder containing carbohydrate and citrate ... Definition: One unit will convert 1.0 ... to D -glucose 6-phosphate per ... C. Chem comp: Protein ...
... Vector is specifically designed to target and ... Saccharomyces cerevisiae. Displayed proteins can be analyzed ... or putative ligands. pYD1 uses the a-agglutinin ... domains Aga1 and Aga2 to display recombinant ...
... Polyclonal Antibody against Aph-1a (Aph-1aL,S Loop ... gamma secretase is a multiprotein complex ... Pen-2; all four proteins are necessary ... secretase complex catalyzes cleavage of a ...
TGase3 (S-20)...
Biology Products: